IN BRIEF: Apollon Formularies acquires Aion intellectual property

Writer,

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Apollon Formularies PLC - London-based medical cannabis pharmaceutical firm - Acquires certain intellectual property assets from AI Pharmaceuticals Ltd, a wholly-owned subsidiary of Aion Therapeutic Inc, for £95,957 and the issue of 4.3 million ordinary shares. Royalty fees of 4% will be due to Aion for net revenue on products derived or based on the IP assets. IP assets cover patents, data and test results for cancers, inflammation, as cannabis compositions and mushroom compositions for the treatment of cancer.

Current stock price: last traded at 2.5 pence

12-month change: down 38%

Copyright 2022 Alliance News Limited. All Rights Reserved.